Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction...

Keywords

TrastuzumabMedicineInternal medicineCapecitabineChemotherapyRegimenCancerOncologyClinical endpointChemotherapy regimenGastroenterologySurgeryBreast cancerClinical trialColorectal cancer

Affiliated Institutions

Related Publications

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median ov...

2021 The Lancet 2580 citations

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran , Nils Homann , Claudia Pauligk +54 more

Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-ba...

2019 The Lancet 2355 citations

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Anthony W. Tolcher , Steven Sugarman , Karen A. Gelmon +7 more

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is direc...

1999 Journal of Clinical Oncology 266 citations

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith , Marion Procter , Richard D. Gelber +21 more

2007 The Lancet 1503 citations

Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models

Kaori Fujimoto-Ouchi , Fumiko Sekiguchi , Hideyuki Yasuno +3 more

2006 Cancer Chemotherapy and Pharmacology 192 citations

Publication Info

Year: 2010
Type: article
Volume: 376
Issue: 9742
Pages: 687-697
Citations: 7049
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

7049

OpenAlex

Cite This

APA Style

                            
                                
                                    Yung‐Jue Bang, 
                                
                                    Eric Van Cutsem, 
                                
                                    A. Feyereislova
                                
                                et al.
                            
                            (2010). 
                            Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. 
                            The Lancet
                            , 376
                            (9742)
                            , 687-697.
                            https://doi.org/10.1016/s0140-6736(10)61121-x
                        

Identifiers

DOI: 10.1016/s0140-6736(10)61121-x